Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 9/20 | 0.52 |
| ▸ | CYP11B2 | P19099 | 8/20 | 0.52 |
| ▸ | EIF2AK3 | Q9NZJ5 | 7/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | EIF2AK1 | Q9BQI3 | 2/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | CASP2 | P42575 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4527947 | 0.80 | CYP11B1 (0.78) | CYP11B1CYP11B2EIF2AK3HTR2AHTR2C | |
| SCHEMBL4521895 | 0.80 | CYP11B2 (0.48) | CYP11B1CYP11B2EIF2AK3HTR2AHTR2C | |
| SCHEMBL4521887 | 0.75 | CYP11B1 (0.47) | CYP11B1CYP11B2EIF2AK3HTR2AHTR2C | |
| SCHEMBL4525150 | 0.75 | EIF2AK3 (0.59) | CYP11B1CYP11B2EIF2AK3HTR2AHTR2C | |
| SCHEMBL4533237 | 0.74 | CYP11B1 (0.48) | CYP11B1CYP11B2EIF2AK3HTR2AHTR2C | |
| SCHEMBL4521679 | 0.74 | CYP11B1 (0.48) | CYP11B1CYP11B2EIF2AK3HTR2AHTR2C | |
| SCHEMBL4525608 | 0.73 | ROCK2 (0.46) | MEN1KMT2A | |
| SCHEMBL10259875 | 0.73 | HTR2A (0.58) | CYP11B1CYP11B2EIF2AK3HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL4531569 | 0.72 | HTR2A (0.57) | CYP11B1CYP11B2EIF2AK3HTR2AHTR2C | |
| SCHEMBL4521891 | 0.72 | CYP11B2 (0.48) | CYP11B1CYP11B2EIF2AK3HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211919-B2 | Amide derivatives as rock inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ROCK1, ROCK2, RHOA | CYP11B1 971/4885CYP11B2 911/4885EIF2AK3 1798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.